GnRH agonist pretreatment with or without letrozole before embryo transfer in women with adenomyosis: does prior implantation failure modify the benefit? A retrospective cohort study

In: https://etd.adm.unipi.it/theses/available/etd-10142026-183828/ · 2026 · W7225933009
Observational OA: green CC0
🔓 Open OA copy View on OpenAlex

Abstract

Background. Adenomyosis is an oestrogen-dependent uterine disorder associated with adverse reproductive outcomes, with an impact that varies according to disease and embryo characteristics. The reproductive benefit of hormonal suppression before embryo transfer remains uncertain. Previous transfer history may help refine patient selection for a more individualised pretreatment strategy. Objectives. To assess the association between combined gonadotrophin-releasing hormone agonist (GnRHa) plus letrozole pretreatment and live birth per transfer in women with adenomyosis and at least one documented previous negative β-hCG result, and to explore variation according to the number of previous negative results. Materials and methods. This retrospective multicentre cohort included fresh and frozen embryo transfers performed at IVI Rome and IVI Bologna between January 2016 and September 2025 in women with ultrasound-diagnosed adenomyosis, requiring at least one direct MUSA feature. The overall cohort comprised 262 transfers in 129 women; the main population included 109 transfers in 59 women, with 74 receiving GnRHa plus letrozole and 35 no pretreatment. Logistic generalised estimating equations (GEE) with an independent working correlation and patient-clustered robust standard errors accounted for repeated transfers and adjusted for patient age, oocyte age and embryo quality. The primary model included 103 complete-case transfers in 58 women. Exploratory interaction models used 254 transfers in 128 women. A sensitivity analysis was restricted to hormone replacement therapy (HRT) cycles. Results. In the main population, live birth occurred after 32/74 pretreated transfers (43.2%) and 7/35 transfers without pretreatment (20.0%): an unadjusted absolute difference of 23.2 percentage points; adjusted odds ratio (aOR) 3.30, 95% CI 1.17–9.35; p = 0.025. Positive β- hCG occurred in 44/74 (59.5%) versus 11/35 (31.4%; aOR 3.09, 95% CI 1.20–7.94; p = 0.019). Clinical pregnancies numbered 39/74 (52.7%) versus 9/35 (25.7%); losses among β- hCG-positive pregnancies numbered 12/44 (27.3%) versus 4/11 (36.4%). The interaction between pretreatment and documented prior negative transfers yielded p = 0.041. Across 0, 1 and ≥2 previous negative results, live-birth aORs were 0.77 (95% CI 0.34–1.74), 1.85 (0.51– 6.70) and 5.93 (1.19–29.5), respectively; the live-birth trend test yielded p = 0.060. The HRT model, comprising 84 transfers in 52 women, yielded an aOR of 4.27 (95% CI 0.98–18.6; p = 0.053). Conclusions. Combined pretreatment was associated with higher odds of live birth in women with documented prior negative transfers. The observed signal supports further evaluation of reproductive history in targeted patient selection. The observational design and exploratory analyses warrant prospective confirmation before treatment recommendations can be established.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-11-19T06:04:33.792782+00:00
License: CC0 · commercial use OK